Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 8208065, 15 pages
https://doi.org/10.1155/2017/8208065
Research Article

Suppression of Excessive Histone Deacetylases Activity in Diabetic Hearts Attenuates Myocardial Ischemia/Reperfusion Injury via Mitochondria Apoptosis Pathway

Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province 430060, China

Correspondence should be addressed to Zhongyuan Xia; moc.nuyila@zmnauygnohzaix

Received 10 July 2016; Revised 11 November 2016; Accepted 22 November 2016; Published 16 January 2017

Academic Editor: Hiroshi Okamoto

Copyright © 2017 Yang Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Li, M. Carey, and J. L. Workman, “The role of chromatin during transcription,” Cell, vol. 128, no. 4, pp. 707–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. I. V. Gregoretti, Y.-M. Lee, and H. V. Goodson, “Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis,” Journal of Molecular Biology, vol. 338, no. 1, pp. 17–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Thiagalingam, K.-H. Cheng, H. J. Lee, N. Mineva, A. Thiagalingam, and J. F. Ponte, “Histone deacetylases: unique players in shaping the epigenetic histone code,” Annals of the New York Academy of Sciences, vol. 983, pp. 84–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. W. S. Xu, R. B. Parmigiani, and P. A. Marks, “Histone deacetylase inhibitors: molecular mechanisms of action,” Oncogene, vol. 26, no. 37, pp. 5541–5552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Khochbin, A. Verdel, C. Lemercier, and D. Seigneurin-Berny, “Functional significance of histone deacetylase diversity,” Current Opinion in Genetics and Development, vol. 11, no. 2, pp. 162–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Grunstein, “Histone acetylation in chromatin structure and transcription,” Nature, vol. 389, no. 6649, pp. 349–352, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Moser, A. Hagelkruys, and C. Seiser, “Transcription and beyond: the role of mammalian class I lysine deacetylases,” Chromosoma, vol. 123, no. 1-2, pp. 67–78, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Martin, R. Kettmann, and F. Dequiedt, “Class IIa histone deacetylases: regulating the regulators,” Oncogene, vol. 26, no. 37, pp. 5450–5467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Thal, P. Krishnamurthy, A. R. MacKie et al., “Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair,” Circulation Research, vol. 111, no. 2, pp. 180–190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. S. Vadvalkar, C. N. Baily, S. Matsuzaki, M. West, Y. A. Tesiram, and K. M. Humphries, “Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a chronic model of Type 1 diabetes,” Biochemical Journal, vol. 449, no. 1, pp. 253–261, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-A. Lee, D.-Y. Lee, H.-M. Cho, S.-Y. Kim, Y. Iwasaki, and I. K. Kim, “Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension,” Circulation Research, vol. 112, no. 7, pp. 1004–1012, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. C. M. Trivedi, Y. Luo, Z. Yin et al., “Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity,” Nature Medicine, vol. 13, no. 3, pp. 324–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Zhang, X. Qin, Y. Zhao et al., “Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis,” Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 285–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Xu, X. Lin, L. Andrews, D. Patel, P. D. Lampe, and R. D. Veenstra, “Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication,” Frontiers in Pharmacology, vol. 4, article 44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. T. C. Zhao, G. Cheng, L. X. Zhang, Y. T. Tseng, and J. F. Padbury, “Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury,” Cardiovascular Research, vol. 76, no. 3, pp. 473–481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Kong, P. Tannous, G. Lu et al., “Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy,” Circulation, vol. 113, no. 22, pp. 2579–2588, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. L. Antos, T. A. McKinsey, M. Dreitz et al., “Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors,” Journal of Biological Chemistry, vol. 278, no. 31, pp. 28930–28937, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Chen, J. Du, Y. T. Zhao et al., “Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice,” Cardiovascular Diabetology, vol. 14, no. 1, article 99, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Lopez-de-andres, R. Jimenez-Garcia, V. Hernandez-Barrera et al., “National trends over one decade in hospitalization for acute myocardial infarction among Spanish adults with type 2 diabetes: cumulative incidence, outcomes and use of percutaneous coronary intervention,” PLoS ONE, vol. 9, no. 1, Article ID e85697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Li, Z. Liu, J. Wang et al., “Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats,” Cardiovascular Diabetology, vol. 12, no. 1, p. 133, 2013. View at Publisher · View at Google Scholar
  21. S. Hicks, N. Labinskyy, B. Piteo et al., “Type II diabetes increases mitochondrial DNA mutations in the left ventricle of the Goto-Kakizaki diabetic rat,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 304, no. 7, pp. H903–H915, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. K. Sharma and D. Khanna, “Diabetes mellitus associated cardiovascular signalling alteration: a need for the revisit,” Cellular Signalling, vol. 25, no. 5, pp. 1149–1155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Muravyeva, I. Baotic, M. Bienengraeber et al., “Cardioprotection during diabetes: the role of mitochondrial DNA,” Anesthesiology, vol. 120, no. 4, pp. 870–879, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Koka, A. Das, F. N. Salloum, and R. C. Kukreja, “Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice,” Free Radical Biology and Medicine, vol. 60, pp. 80–88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Przyklenk, “Reduction of myocardial infarct size with ischemic ‘conditioning’ : physiologic and technical considerations,” Anesthesia and Analgesia, vol. 117, no. 4, pp. 891–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Engbersen, N. P. Riksen, M. J. Mol et al., “Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study,” Cardiovascular Diabetology, vol. 11, article 124, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Ferdinandy, R. Schulz, and G. F. Baxter, “Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning,” Pharmacological Reviews, vol. 59, no. 4, pp. 418–458, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. C. Sloan, F. Moukdar, C. R. Frasier et al., “Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 5, pp. 1009–1018, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Ban, A. J. Cooper, S. Samuel et al., “Phosphatidylinositol 3-kinase γ is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning,” Circulation Research, vol. 103, no. 6, pp. 643–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Wu, Z.-Y. Xia, J. Dou et al., “Protective effect of ginsenoside Rb1 against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats,” Molecular Biology Reports, vol. 38, no. 7, pp. 4327–4335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Liu, B. Zhou, Z.-Y. Xia et al., “Hyperglycemia-induced inhibition of DJ-1 expression compromised the effectiveness of ischemic postconditioning cardioprotection in rats,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 564902, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Shi, L. Chen, H. Wang et al., “Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes,” Biochemical and Biophysical Research Communications, vol. 430, no. 2, pp. 827–832, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Wang, Y. Shi, X. Jiang et al., “HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 9, pp. 2853–2858, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. T. C. Zhao, J. Du, S. Zhuang, P. Liu, and L. X. Zhang, “HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1,” PLoS ONE, vol. 8, no. 6, Article ID e65474, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Paillard, E. Tubbs, P.-A. Thiebaut et al., “Depressing mitochondria-reticulum interactions protects cardiomyocytes from lethal hypoxia-reoxygenation injury,” Circulation, vol. 128, no. 14, pp. 1555–1565, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Li and N. K. Fukagawa, “Age-related changes in redox signaling and VSMC function,” Antioxidants and Redox Signaling, vol. 12, no. 5, pp. 641–655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Ganesan, B. L. Unger, A. T. Comstock et al., “Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A,” Thorax, vol. 68, no. 2, pp. 131–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Shimazu, M. D. Hirschey, J. Newman et al., “Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor,” Science, vol. 339, no. 6116, pp. 211–214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. K.-J. Yin, C. Y. Hsu, X.-Y. Hu et al., “Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-β peptide-induced cerebrovascular endothelial cell death,” Journal of Neuroscience, vol. 26, no. 8, pp. 2290–2299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. P. A. Marks, “Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1799, no. 10-12, pp. 717–725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Zhu, S. Evans, B. Yan et al., “Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells,” Circulation, vol. 118, no. 21, pp. 2156–2165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Rafehi, A. Balcerczyk, S. Lunke et al., “Vascular histone deacetylation by pharmacological HDAC inhibition,” Genome Research, vol. 24, no. 8, pp. 1271–1284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Zhao, C.-N. Chen, N. Hajji et al., “Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid,” Circulation, vol. 126, no. 4, pp. 455–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Khan and G. B. Jena, “Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat,” Chemico-Biological Interactions, vol. 213, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Khan and G. Jena, “Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-β1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats,” Food and Chemical Toxicology, vol. 73, pp. 127–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Xie, Y. Kong, W. Tan et al., “Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy,” Circulation, vol. 129, no. 10, pp. 1139–1151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. T. A. McKinsey, “Therapeutic potential for HDAC inhibitors in the heart,” Annual Review of Pharmacology and Toxicology, vol. 52, pp. 303–319, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Yu, M. Lu, P. Wang, and X. Chen, “Trichostatin A ameliorates myocardial ischemia/reperfusion injury through inhibition of endoplasmic reticulum stress-induced apoptosis,” Archives of Medical Research, vol. 43, no. 3, pp. 190–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Zhou, L. Qiu, Y. Sun et al., “Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells,” International Journal of Oncology, vol. 29, no. 1, pp. 269–278, 2006. View at Google Scholar · View at Scopus
  51. B. Huisamen, “Protein kinase B in the diabetic heart,” Molecular and Cellular Biochemistry, vol. 249, no. 1-2, pp. 31–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Tsang, D. J. Hausenloy, M. M. Mocanu, R. D. Carr, and D. M. Yellon, “Preconditioning the diabetic heart: the importance of Akt phosphorylation,” Diabetes, vol. 54, no. 8, pp. 2360–2364, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Peng, J. Ma, X. Gao, P. Tian, W. Li, and L. Zhang, “High glucose induced oxidative stress and apoptosis in cardiac microvascular endothelial cells are regulated by FoxO3a,” PLoS ONE, vol. 8, no. 11, Article ID e79739, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Ren, H.-C. Tu, H. Kim et al., “BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program,” Science, vol. 330, no. 6009, pp. 1390–1393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. G. Wang, T. Hamid, R. J. Keith et al., “Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart,” Circulation, vol. 121, no. 17, pp. 1912–1925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Korge, H. M. Honda, and J. N. Weiss, “Protection of cardiac mitochondria by diazoxide and protein kinase C: implications for ischemic preconditioning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 3312–3317, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. D. A. Kubli and Å. B. Gustafsson, “Mitochondria and mitophagy: the yin and yang of cell death control,” Circulation Research, vol. 111, no. 9, pp. 1208–1221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. S. E. Aune, D. J. Herr, S. K. Mani, and D. R. Menick, “Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion,” Journal of Molecular and Cellular Cardiology, vol. 72, pp. 138–145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Yoshida, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” Tanpakushitsu Kakusan Koso, vol. 52, supplement 13, pp. 1788–1789, 2007. View at Google Scholar · View at Scopus